Roivant Sciences Ltd. (ROIV) stock
Close on Nov 12, 2026Market cap $28.89BP/E –Yield –
Roivant Sciences Ltd. grew revenue 102.1% to $41.08M over the twelve months to Sep 30, 2026. Free cash flow was -$33.34M. At the latest close the market valued the company at $28.89B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $28.89B
- P/E ratio
- –
- Price to sales
- 703.12
- Price to book
- 7.18
- Dividend yield
- –
- Free cash flow yield
- -0.12%
Fundamentals
- Revenue
- $41.08M
- Net income
- -$344.35M
- EPS, diluted
- -$0.49
- Free cash flow
- -$33.34M
- Book value per share
- $5.56
- Diluted shares
- 723M
Trading
- Next earnings
- Feb 5, 2027 (estimated, before the open)
- Previous close
- $41.85
- Open
- $41.39
- Day's range
- $39.92 – $41.50
- Volume
- 8,744,049
- Average volume (20 days)
- 8,500,849
- Index membership
- Russell 1000 (since Jun 2023)
- Beta (5 years)
- 0.85
- 52-week range
- $19.96 – $42.50
- RSI (14 days)
- 59.1
- Volatility (1 year)
- 48.1%
- Relative volume
- 1.22×
- WACC
- 9.1%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWB), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ROIV | S&P 500 | Difference | ROIV per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +15.6% | -2.7% | +18.3 pts | ||
| 3 months | +10.6% | -1.7% | +12.3 pts | ||
| Year to date | +84.3% | +11.9% | +72.4 pts | ||
| 1 year | +87.6% | +12.0% | +75.6 pts | ||
| 3 years | +353.9% | +78.2% | +275.7 pts | +65.6% | +21.2% |
| 5 years | +376.1% | +73.2% | +302.8 pts | +36.6% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Roivant Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- News
- Update
- Results
About Roivant Sciences
Pharmaceutical Preparations
Roivant is a biopharmaceutical company that focuses on accelerating the development and commercialization of medicines across diverse therapeutic areas. The company organizes its operations through specialized, nimble subsidiary companies known as “Vants,” while also incubating early-stage discovery ventures and complementary health technology businesses. Its clinical pipeline centers on therapeutic candidates such as brepocitinib, an oral small-molecule dual inhibitor targeting inflammatory and immune conditions; IMVT-1402, a fully human monoclonal antibody directed against IgG-mediated autoimmune indications; and mosliciguat, an inhaled formulation under evaluation for pulmonary vascular disorders. Roivant targets patient populations suffering from severe autoimmune, dermatological, rheumatological, and respiratory conditions where current medical options remain inadequate.
Company profile, executives and historyRoivant Sciences stock: common questions
What is Roivant Sciences's stock price?
ROIV closed at $39.99 on Nov 12, 2026, down 4.44% on the day. Over the past 52 weeks it traded between $19.96 and $42.50.
What is Roivant Sciences's market cap?
Roivant Sciences was worth $28.89B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ROIV's P/E ratio?
Roivant Sciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.49), so it has no meaningful P/E ratio.
How much revenue does Roivant Sciences make?
Roivant Sciences reported revenue of $41.08M for the twelve months to Sep 30, 2026, up 102.1% from a year earlier.
Does Roivant Sciences pay a dividend?
No. Roivant Sciences has not paid a cash dividend over the last twelve months.
When does Roivant Sciences report earnings next?
Roivant Sciences is expected to report Q3 FY2026 results on Feb 5, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ROIV stock performed over the past year?
Including dividends, ROIV returned +87.6% over the past year, against +12.0% for the S&P 500.
How many ROIV shares are sold short?
46M shares were sold short at the latest FINRA report, 7.34% of the float, or 6.1 days of average trading volume.
Who are Roivant Sciences's competitors?
Companies most similar to Roivant Sciences by business, industry and size include KROS, VRDN, VTVT, QTTB, NAMS.
See a number that looks wrong?